|Mr. Armando Anido||Chairman and Chief Exec. Officer||901.21k||N/A||59|
|Ms. Terri B. Sebree||Pres||681.77k||N/A||59|
|Mr. James E. Fickenscher||Chief Financial Officer and VP of Corp. Devel.||260.09k||N/A||53|
|Mr. William C. Roberts||VP of Investor Relations & Corp. Communications||N/A||N/A||48|
|Ms. Suzanne M. Hanlon||VP of HR, Gen. Counsel and Sec.||N/A||N/A||60|
Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Zynerba Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.